Jun 16, 2025
Оfftopic Community
Оfftopic Community
Forums
New posts
Search forums
What's new
Featured content
New posts
New media
New media comments
New resources
New profile posts
Latest activity
Media
New media
New comments
Search media
Resources
Latest reviews
Search resources
Members
Current visitors
New profile posts
Search profile posts
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Install the app
Install
Forums
Information & News
RSS News
Health and Fitness
Treatment For Bone Metastases Can Improve Overall Survival
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="tD33NAt" data-source="post: 2710129" data-attributes="member: 124445"><p>It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss. A study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that the bone metastases drug denosumab was associated with improved overall survival compared with zoledonic acid (ZA)...<img src="http://feeds.feedburner.com/~r/mnt/healthnews/~4/XPfO9uML1Ns" alt="" class="fr-fic fr-dii fr-draggable " data-size="" style="" /></p><p></p><p><a href="http://feedproxy.google.com/~r/mnt/healthnews/~3/XPfO9uML1Ns/252908.php" target="_blank">More...</a></p></blockquote><p></p>
[QUOTE="tD33NAt, post: 2710129, member: 124445"] It is common for patients initially diagnosed with lung cancer to have the cancer spread to sites like the liver, brain and bone. One of the most frequent sites of metastases is the bone, with an estimated 30 to 40 percent of patients with non-small-cell lung cancer (NSCLC) developing bone loss. A study published in the December 2012 issue of the International Association for the Study of Lung Cancer's (IASLC) Journal of Thoracic Oncology, shows that the bone metastases drug denosumab was associated with improved overall survival compared with zoledonic acid (ZA)...[IMG]http://feeds.feedburner.com/~r/mnt/healthnews/~4/XPfO9uML1Ns[/IMG] [url=http://feedproxy.google.com/~r/mnt/healthnews/~3/XPfO9uML1Ns/252908.php]More...[/url] [/QUOTE]
Insert quotes…
Name
Verification
Please enable JavaScript to continue.
Loading…
Post reply
Top